期刊文献+

LC-ESI-MS/MS法快速测定人血浆中帕洛诺司琼的浓度

Rapid determination of palonosetron in human plasma by LC-ESI-MS/MS
原文传递
导出
摘要 目的建立快速测定人血浆中帕洛诺司琼浓度的高效液相色谱串联质谱电喷雾检测(LC-ESI-MS/MS)法。方法以Aglent C_(18)反相柱(150 mm×4.6 mm,5μm)为色谱柱,流动相为乙腈:0.04 mol·L^(-1)甲酸铵水溶液(含0.04%甲酸)=80:20(V/V),流速0.8mL·min^(-1),柱温25℃,醋酸乙酯:二氯甲烷(4:1,V:V)为提取剂。样品经电喷雾离子源正离子化后,通过三重四级杆串联质谱仪,采用选择反应监测(SRM)模式对帕洛诺司琼(m/z 297.2→82.2)和内标地西泮(m/z285.1→154.0)进行测定。结果帕洛诺司琼高(8μg·L^(-1))、中(5μg·L^(-1))、低(0.1μg·L^(-1))3个质量浓度血浆溶液的RSD均<15%;线性范围为0.05~10μg·L^(-1),回归方程为F=1.831 9ρ+0.009 8,r=0.996 4(n=9),权重系数为1/ρ~2,分析方法的定量下限为0.05μg·L^(-1)。结论该方法灵敏、准确、简单、快速,可用于帕洛诺司琼临床血药浓度监测和药动学研究。 AIM To set up a LC-ESI-MS/MS method for palonosetron assay in human plasma. METHODS Palonosetron was extracted with ethyl acetate -dichloromethane. The residues were analyzed with a LC-ESI-MS/MS sys- tem (Agilent TC C18 column, 150 mm × 4.6 mm,5 μm) with the mobile phase consisted of acetonitrile with 0.04 mol· L^-1 arranonium formate (0.04% formic acid) = 80:20 (V/V) .The Agilent 6 410 triple quad mass spectrometer system equipped with an electrospray ionization ion-trap source was used as the detector and operated in the positive ion mode. Selected reaction monitoring(SRM) by using precursor to produce ion combinations of m/z 297.2→82.2 and m/z 285.1→154.0 was performed to detect palonosetron and the internal standard, respectively. RESULTS The average extraction recoveries for palonosetron were 78.86%, 78.35% and 80.15%, respectively. The within-day ( n = 5) and between-day ( n = 3) precision of variation was less than 15%. The calibration curve for palonosetron was linear within the range of 0.05 - 10 μg· L^- 1. The limit of quantitation for palonosetron was 0.05 μg· L^- 1 CONCLUSION The method provides a sensitive, accurate, simple and rapid analytical procedure for clinical monitoring of palonosetron and its phamacokinetic studies.
出处 《中国临床药学杂志》 CAS 2009年第6期334-338,共5页 Chinese Journal of Clinical Pharmacy
基金 广东省自然科学研究基金立项资助(8151037001000001)
关键词 帕洛诺司琼 血药浓度 高效液相色谱串联质谱电喷雾法 palonosetron plasma concentration LC-ESI-MS/MS
  • 相关文献

参考文献4

二级参考文献17

  • 1林清强,叶锦林.新型5-HT3受体拮抗剂帕洛诺司琼[J].中国科技信息,2005(11):157-157. 被引量:12
  • 2陈长水,杨先启.反相高效液相色谱法测定人肝微粒体中帕洛诺司琼的含量[J].药学实践杂志,2005,23(3):169-171. 被引量:3
  • 3赵燕,赵莹.气相色谱法同时测定帕洛诺司琼中的8种有机溶剂残留量[J].预防医学论坛,2007,13(1):52-53. 被引量:4
  • 4[4]Hunt TL,Gallagher SC,Cullen MT Jr,et al.Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects[J].Clin pharmacol.2005 May;45(5):589-596.
  • 5[5]Stoltz R,Cyong JC,Shah A,et al.Pharmacokinetic and safety evaluation of palonosetron,a 5-hydroxytryptamine-3 receptor antagonist,in U.S.and Japanese healthy subjects[J].Clin Pharmacol.2004 May;44(5):520-531.
  • 6HFSKETH P J.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18 (2):163-173.
  • 7LINDLEY C M,BERNARD S,FIELDS S M.Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population[J].J Clin Oncol,1989,7 (8):1142-1149.
  • 8GREGORY R E,ETTINGER D S.5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.A comparison of their pharmacology and clinical efficacy[J].Drugs,1998,55(2):173-189.
  • 9STOLTZ R,CYONG J,SHAH A,et al.Pharmacokinetic and safety evaluation of palonosetron,a 5-hydroxytryptamine-3 receptor antagonist,in US and Japanese healthy subjects[J].J Clin Pharmacol,2004,44(5):520-531.
  • 10STOLTZ R,PARISI S,SHAH A,et al.Pharmacokinetics,metabolism and excretion of intravenous[14C]-palonosetron in healthy human volunteers[J].Biopharm Drug Dispos,2004,25(8):329-337.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部